Pull to refresh
Logo
Mayo Clinic

Mayo Clinic

Academic Medical Center

Appears in 4 stories

Stories

Senolytic drug pair improves liver fibrosis in pilot MASH trial

New Capabilities

Originator of the D+Q senolytic approach

Eight of 17 patients whose fatty liver disease had progressed to scarring saw their fibrosis improve after 21 weeks of intermittent treatment with two drugs. One of 14 on placebo did. The randomized, placebo-controlled result, published in Nature Metabolism, is the first controlled evidence that clearing senescent cells can reverse liver fibrosis in people.

Updated 5 days ago

Custom RNA drug improves rare ALS in first personalized case

New Capabilities

Conducted the N-of-1 clinical study

A physician with a rare inherited form of amyotrophic lateral sclerosis (ALS) received a drug built around his own gene mutation, the first therapy designed for this genetic form of the disease. A year after his first dose, his neuron-damage biomarker fell into the normal range and he kept practicing medicine.

Updated Sep 21

Helix builds North America's largest linked clinico-genomic dataset

New Capabilities

Anchor sequencing partner for Helix

Helix said its GenoSphere platform now holds more than 500,000 linked clinico-genomic records. That makes it the largest such dataset in North America. The San Mateo company also released the first of a planned set of artificial intelligence tools built to mine that data for drug targets.

Updated Jun 2

Mayo Clinic AI detects pancreatic cancer years before diagnosis

New Capabilities

Developer of REDMOD; running the AI-PACED clinical trial

Pancreatic cancer kills nearly nine in ten patients within five years, mostly because doctors catch it too late to operate. On April 28, 2026, Mayo Clinic researchers published a validation study showing their artificial intelligence model can flag the disease on routine CT scans up to three years before a clinical diagnosis.

Updated May 31